Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron to Participate at Upcoming Investor Conferences in April
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Geron secures 12-2 AdComm vote in favor of blood cancer drug
Geron`s blood disorder drug gets FDA advisers` backing
US FDA staff raises concerns on Geron`s blood disorder drug
Geron Reports Fourth Quarter and Full Year 2023 Financial Results
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)